Gland Pharma AGM 2026: Key dates, VC mode, KYC rules

AGM scheduled on August 25, 2026

Gland Pharma Limited has scheduled its 48th Annual General Meeting (AGM) for Tuesday, August 25, 2026 at 11:00 A.M. IST. The company will conduct the AGM through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The format follows Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and relevant Ministry of Corporate Affairs (MCA) circulars. Gland Pharma has also published newspaper advertisements in English and Telugu to inform shareholders about the meeting and related arrangements.

A key practical implication for investors is that participation will be remote, without physical presence at a common venue. The company has specified a deemed venue for legal and compliance purposes, linked to its corporate office in Hyderabad. Shareholders are expected to rely on electronic access for the notice and FY26 annual report documents. The company has also reiterated processes for e-voting and KYC updates, especially for investors holding shares in physical form.

Virtual format and deemed venue in Hyderabad

The AGM will be held entirely via VC/OAVM, allowing members to attend and participate remotely. Even though it is a virtual meeting, the deemed venue is fixed at Gland Pharma’s corporate office: Plot No. 11 & 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad 502307, Telangana. The quorum will be determined under Section 103 of the Companies Act, 2013.

The company has also listed its registered office address as Survey No. 143-148, 150 & 151, Near Gandimaisamma ‘X’ Roads, D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal, Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India. Contact details provided include Tel: +91-40-30510999 and Fax: +91-40-30510800. Shareholders seeking clarifications or inspection of documents electronically can use the company’s investor email address, investors@glandpharma.com.

Live webcast and where shareholders can watch

Gland Pharma said the live webcast of the AGM will be provided by NSDL through www.evoting.nsdl.com. This enables members to view the proceedings remotely. The company has also indicated that AGM-related documents will be accessible through multiple official channels, including the company website and stock exchange platforms.

For shareholders, this setup makes NSDL’s e-voting and webcast portal a central access point for both watching the AGM and following the voting process. The company has urged members to review the remote e-voting instructions in the AGM Notice to cast votes effectively.

SEBI Third Amendment Regulations 2024 and digital-only dispatch

A central update in the communication is the mode of dispatch for AGM documents. In alignment with the SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024, Gland Pharma will dispatch the AGM Notice and FY26 documents only via electronic mode. The electronic set includes the Notice of AGM, Standalone and Consolidated Financial Statements for FY26, Board’s Report, and Auditor’s Report.

The company has stated that physical copies will not be sent to members who have not registered their email addresses with the Registrar and Transfer Agent (RTA) or with Depositories. For shareholders without registered email IDs, the company will send a letter containing a weblink and/or QR Code to access the AGM notice and annual report online. This approach is intended to ensure document access while maintaining digital-first distribution.

What physical and demat shareholders need to do

Gland Pharma has clearly separated action points by holding type. Physical shareholders must submit request forms with supporting documents to MUFG Intime India Private Limited at C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai – 400 083. Demat shareholders are expected to update email IDs and KYC details with their respective Depository Participants.

The company’s communication also highlights the practical impact of incomplete KYC for physical shareholders. As referenced, a SEBI Master Circular dated May 7, 2024 notes that physical shareholders who have not completed PAN, contact details, bank account details, and specimen signature by April 1, 2024 can only lodge grievances or receive dividends after furnishing these details and nomination. This is positioned as a compliance-driven requirement affecting access to shareholder services.

Where AGM documents will be available online

Beyond direct email dispatch, the company has stated that the AGM notice and annual report documents will be available on:

• Gland Pharma’s website (www.glandpharma.com)
• BSE Limited (www.bseindia.com)
• NSE India (www.nseindia.com)
• NSDL (www.evoting.nsdl.com)

This multi-platform availability is relevant for shareholders who depend on exchange disclosures or NSDL access for meeting participation. It also serves as a fallback for those awaiting email registration updates.

Key AGM details at a glance

Earnings conference call on August 10, 2026

Separately, Gland Pharma will host an earnings conference call for investors and analysts on Monday, August 10, 2026 at 18:30 hours (IST). The scheduled duration is 60 minutes. The company has provided a universal access set of numbers and toll-free dial-ins for several regions.

This call is relevant for market participants tracking the company’s financial performance and management commentary ahead of the AGM. While the company has not detailed the agenda in the shared information, the timing and structured access details indicate a standard earnings interaction format.

Context from last year’s AGM and dividend disclosures

The company’s prior AGM records show the 47th AGM was held on August 28, 2025, with related exchange announcements dated May 20, 2025 and outcomes published on August 28, 2025. The 47th AGM was also conducted through video conferencing and webcast. The company’s AGM proceedings note that VC attendance capacity was provided to a minimum of 1,000 shareholders on a first come, first serve basis.

For shareholder voting in 2025, the company stated that remote e-voting commenced at 9:00 AM IST on Monday, August 25, 2025 and ended at 5:00 PM IST on Wednesday, August 27, 2025. Voting rights were reckoned based on shares held as of the cut-off date, August 21, 2025. The company also disclosed that the Board recommended a final dividend of INR 18 per equity share for the financial year ended March 31, 2025, with a record date of August 14, 2025, subject to shareholder approval at the AGM.

In addition, the shared information includes a disclosure stating that the board approved a final dividend of Rs. 20 per share, subject to approval of shareholders in the ensuing 48th AGM.

Stock price reference and investor contact points

The shared information notes Gland Pharma’s last traded price as Rs 1,870.20 as on 04 Feb, 2026, 09:56 AM IST. Such price references are typically used by investors to contextualise corporate actions and upcoming meeting dates.

For investor relations, Shriniwas Pradeep Dange is listed as the point of contact and can be reached at investors@glandpharma.com. For corporate governance matters, Sampath Kumar Pallerlamudi is indicated as the Company Secretary and Compliance Officer. These contact points matter for shareholders seeking clarifications on AGM participation, electronic dispatch, and KYC-related issues.

Conclusion

Gland Pharma’s 48th AGM on August 25, 2026 will be a VC/OAVM-only meeting, with NSDL providing webcast access and e-voting infrastructure. The company has reiterated that FY26 AGM documents will be sent only electronically under SEBI’s Third Amendment Regulations 2024, making email registration and KYC completion critical, especially for physical shareholders. Investors and analysts also have a scheduled checkpoint ahead of the AGM through the earnings conference call on August 10, 2026.